These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28083796)

  • 1. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.
    Yogurtcu ON; Sauna ZE; McGill JR; Tegenge MA; Yang H
    AAPS J; 2019 Aug; 21(5):96. PubMed ID: 31376048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.
    Herskovitz J; Ryman J; Thway T; Lee S; Zhou L; Chirmule N; Meibohm B; Jawa V
    AAPS J; 2017 Mar; 19(2):447-455. PubMed ID: 28070711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
    Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS
    Front Immunol; 2020; 11():1301. PubMed ID: 32695107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Cohen S; Chung S
    Bioanalysis; 2021 Jul; 13(13):1071-1081. PubMed ID: 34124935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.
    Bi V; Jawa V; Joubert MK; Kaliyaperumal A; Eakin C; Richmond K; Pan O; Sun J; Hokom M; Goletz TJ; Wypych J; Zhou L; Kerwin BA; Narhi LO; Arora T
    J Pharm Sci; 2013 Oct; 102(10):3545-55. PubMed ID: 23925953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of the T Cell Response to Protein Biopharmaceuticals.
    Meunier S; de Bourayne M; Hamze M; Azam A; Correia E; Menier C; Maillère B
    Front Immunol; 2020; 11():1550. PubMed ID: 32793213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.
    Cohen S; Myneni S; Batt A; Guerrero J; Brumm J; Chung S
    MAbs; 2021; 13(1):1898831. PubMed ID: 33729092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of therapeutic proteins: influence of aggregation.
    Ratanji KD; Derrick JP; Dearman RJ; Kimber I
    J Immunotoxicol; 2014; 11(2):99-109. PubMed ID: 23919460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.
    Wullner D; Zhou L; Bramhall E; Kuck A; Goletz TJ; Swanson S; Chirmule N; Jawa V
    Clin Immunol; 2010 Oct; 137(1):5-14. PubMed ID: 20708973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity.
    Pratt KP
    Antibodies (Basel); 2018 May; 7(2):. PubMed ID: 31544871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
    Barbosa MD; Kumar S; Loughrey H; Singh SK
    Drug Discov Today; 2012 Dec; 17(23-24):1282-8. PubMed ID: 22796124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of immunogenic response to protein therapeutics.
    Singh SK; Cousens LP; Alvarez D; Mahajan PB
    Biologicals; 2012 Sep; 40(5):364-8. PubMed ID: 22770604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
    Karle A; Spindeldreher S; Kolbinger F
    MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives.
    Di Ianni A; Barbero L; Fraone T; Cowan K; Sirtori FR
    J Pharm Biomed Anal; 2023 Sep; 234():115500. PubMed ID: 37311374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity to biologics: mechanisms, prediction and reduction.
    Sethu S; Govindappa K; Alhaidari M; Pirmohamed M; Park K; Sathish J
    Arch Immunol Ther Exp (Warsz); 2012 Oct; 60(5):331-44. PubMed ID: 22930363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry.
    Neubert H; Grace C; Rumpel K; James I
    Anal Chem; 2008 Sep; 80(18):6907-14. PubMed ID: 18702532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
    Maldonado RA; LaMothe RA; Ferrari JD; Zhang AH; Rossi RJ; Kolte PN; Griset AP; O'Neil C; Altreuter DH; Browning E; Johnston L; Farokhzad OC; Langer R; Scott DW; von Andrian UH; Kishimoto TK
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E156-65. PubMed ID: 25548186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.